FGF23 is a putative marker for bone healing and regeneration
Sascha Goebel
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorJasmin Lienau
Julius Wolff Institut and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Germany
Search for more papers by this authorUlrich Rammoser
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorLothar Seefried
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorJochen Seufert
Department of Endocrinology, University of Freiburg, Freiburg, Germany
Search for more papers by this authorGeorg Duda
Julius Wolff Institut and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Germany
Search for more papers by this authorCorresponding Author
Franz Jakob
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany. T: ++49-931-803-1580; F: ++49-931-803-1599.Search for more papers by this authorRegina Ebert
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorSascha Goebel
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorJasmin Lienau
Julius Wolff Institut and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Germany
Search for more papers by this authorUlrich Rammoser
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorLothar Seefried
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorJochen Seufert
Department of Endocrinology, University of Freiburg, Freiburg, Germany
Search for more papers by this authorGeorg Duda
Julius Wolff Institut and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Germany
Search for more papers by this authorCorresponding Author
Franz Jakob
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany. T: ++49-931-803-1580; F: ++49-931-803-1599.Search for more papers by this authorRegina Ebert
Orthopedic Center for Musculoskeletal Research, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorAbstract
Besides numerous other factors, fibroblast growth factor receptor (FGFR) signaling is involved in fracture healing and bone remodeling. FGF23 is a phosphatonin produced by osteoblastic cells, which signals via FGFR1, thereby exerting effects in bone and kidney. We analyzed if serum FGF23 levels might be an indicator to predict fracture healing and union. FGF23 (C-Term) was elevated on day 3 postoperatively in 55 patients sustaining an exchange of total hip implants due to aseptic loosening. A prospective study of 40 patients undergoing primary hip arthroplasty also showed elevated FGF23 (C-Term) but no change in FGF23 (intact) levels on days 1, 4, and 10 postoperatively. Serum phosphate and phosphate clearance stayed within normal ranges. FGF23 mRNA expression in ovine callus was compared between a standard and delayed course of osteotomy healing. In the standard model, a marked increase in FGF23 mRNA expression compared to the delayed healing situation was observed. Immunohistochemical analysis showed FGF23 production of osteoblasts and granulation tissue in the fracture callus during bone healing. In conclusion, FGF23 is involved in bone healing, can be measured by a sensitive assay in peripheral blood, and is a promising candidate as an indicator for healing processes prone to reunion versus nonunion. © 2009 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res
References
- 1 Riminucci M, Collins MT, Fedarko NS, et al. 2003. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112: 683–692.
- 2 Yoshiko Y, Wang H, Minamizaki T, et al. 2007. Mineralized tissue cells are a principal source of FGF23. Bone 40: 1565–1573.
- 3 Kuro-o M. 2006. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 15: 437–441.
- 4 Kurosu H, Ogawa Y, Miyoshi M, et al. 2006. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120–6123.
- 5 Razzaque MS, Lanske B. 2007. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194: 1–10.
- 6 Lanske B, Razzaque MS. 2007. Premature aging in klotho mutant mice: cause or consequence? Ageing Res Rev 6: 73–79.
- 7 Urakawa I, Yamazaki Y, Shimada T, et al. 2006. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770–774.
- 8 Yamashita T, Yoshioka M, Itoh N. 2000. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277: 494–498.
- 9 Shimada T, Mizutani S, Muto T, et al. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci 98: 6500–6505.
- 10 Berndt T, Craig TA, Bowe AE, et al. 2003. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112: 785–794.
- 11 Fukumoto S, Yamashita T. 2002. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11: 385–389.
- 12 Seufert J, Ebert K, Muller J, et al. 2001. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345: 1883–1888.
- 13 Saito H, Kusano K, Kinosaki M, et al. 2003. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 278: 2206–2211.
- 14 Larsson T, Marsell R, Schipani E, et al. 2004. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 3087–3094.
- 15 Marsell R, Krajisnik T, Goransson H, et al. 2008. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant 23: 827–833.
- 16 Bai X-Y, Miao D, Goltzman D, et al. 2003. The Autosomal Dominant Hypophosphatemic Rickets R176Q Mutation in Fibroblast Growth Factor 23 Resists Proteolytic Cleavage and Enhances in Vivo Biological Potency. J Biol Chem 278: 9843–9849.
- 17 White KE, Carn G, Lorenz-Depiereux B, et al. 2001. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079–2086.
- 18 Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al. 2004. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35: 455–462.
- 19 Benet-Pages A, Orlik P, Strom TM, et al. 2005. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14: 385–390.
- 20 Topaz O, Shurman DL, Bergman R, et al. 2004. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36: 579–581.
- 21 Araya K, Fukumoto S, Backenroth R, et al. 2005. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90: 5523–5527.
- 22 Imanaka M, Iida K, Nishizawa H, et al. 2007. McCune-Albright syndrome with acromegaly and fibrous dysplasia associated with the GNAS gene mutation identified by sensitive PNA-clamping method. Intern Med 46: 1577–1583.
- 23 Kobayashi K, Imanishi Y, Koshiyama H, et al. 2006. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 78: 2295–2301.
- 24 Gerstenfeld LC, Cullinane DM, Barnes GL, et al. 2003. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88: 873–884.
- 25 Dimitriou R, Tsiridis E, Giannoudis PV. 2005. Current concepts of molecular aspects of bone healing. Injury 36: 1392–1404.
- 26 Lienau J, Schell H, Epari DR, et al. 2006. CYR61 (CCN1) protein expression during fracture healing in an ovine tibial model and its relation to the mechanical fixation stability. J Orthop Res 24: 254–262.
- 27 Ai-Aql ZS, Alagl AS, Graves DT, et al. 2008. Molecular Mechanisms Controlling Bone Formation during Fracture Healing and Distraction Osteogenesis. J Dent Res 87: 107–118.
- 28 Lienau J, Schell H, Duda GN, et al. 2007. Differential expression of molecules involved in angiogenesis between uneventful and critical fracture healing. Trans Orthop Res Soc 32: 0355.
- 29 Augat P, Simon U, Liedert A, et al. 2005. Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone. Osteoporos Int 16 (Suppl 2): S36–43.
- 30 Niikura T, Hak DJ, Reddi AH. 2006. Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res 24: 1463–1471.
- 31 Lienau J, Kaletta C, Teifel M, et al. 2005. Morphology and transfection study of human microvascular endothelial cell angiogenesis: an in vitro three-dimensional model. Biol Chem 386: 167–175.
- 32 Chen Y, Whetstone HC, Lin AC, et al. 2007. Beta-Catenin Signaling Plays a Disparate Role in Different Phases of Fracture Repair: Implications for Therapy to Improve Bone Healing. PLoS Medicine 4: e249.
- 33 Gerber HP, Vu TH, Ryan AM, et al. 1999. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623–628.
- 34 Oreffo RO. 2004. Growth factors for skeletal reconstruction and fracture repair. Curr Opin Investig Drugs 5: 419–423.
- 35 Rundle CH, Miyakoshi N, Ramirez E, et al. 2002. Expression of the fibroblast growth factor receptor genes in fracture repair. Clin Orthop Relat Res 403: 253–263.
- 36 Rundle CH, Wang H, Yu H, et al. 2006. Microarray analysis of gene expression during the inflammation and endochondral bone formation stages of rat femur fracture repair. Bone 38: 521–529.
- 37 Nakazawa T, Nakajima A, Seki N, et al. 2004. Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J Orthop Res 22: 520–525.
- 38 Imel EA, Peacock M, Pitukcheewanont P, et al. 2006. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91: 2055–2061.
- 39 Schell H, Epari DR, Kassi JP, et al. 2005. The course of bone healing is influenced by the initial shear fixation stability. J Orthop Res 23: 1022–1028.
- 40 Schell H, Thompson MS, Bail HJ, et al. 2008. Mechanical induction of critically delayed bone healing in sheep: Radiological and biomechanical results. J Biomech 41: 3066–3072.
- 41 Ornitz DM. 2005. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16: 205–213.
- 42 Gerstenfeld LC, Cho TJ, Kon T, et al. 2003. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 18: 1584–1592.
- 43 Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative Ct-method. Nat Protoc 3: 1101–1108.
